Literature DB >> 27263789

Chronic active Epstein-Barr virus infection with marked pericardial effusion successfully treated with allogeneic peripheral blood stem cell transplantation.

Shinichiro Matsui1, Yusuke Takeda, Yusuke Isshiki, Atsuko Yamazaki, Sanshiro Nakao, Koji Takaishi, Yuhei Nagao, Nagisa Hasegawa, Emi Togasaki, Ryoh Shimizu, Chika Kawajiri, Shio Sakai, Naoya Mimura, Masahiro Takeuchi, Chikako Ohwada, Emiko Sakaida, Tohru Iseki, Ken-Ichi Imadome, Chiaki Nakaseko.   

Abstract

A 23-year-old woman presented with a persistent fever and shortness of breath. Computed tomography showed marked pericardial effusion, hepatosplenomegaly, and cervical and mediastinal lymph node swelling. Epstein-Barr virus (EBV) antibody titers were abnormally elevated, and the copy number of EBV-DNA was increased in peripheral blood. Based on these observations, she was diagnosed with chronic active EBV infection (CAEBV). The EBV-infected cells in her peripheral blood were CD4(+)T lymphocytes. Fever and pericardial effusion improved following treatment with a combination of prednisolone, etoposide, and cyclosporine; however, peripheral blood EBV-DNA levels remained high. The patient underwent allogeneic peripheral blood stem cell transplantation from an EBV-seronegative, HLA-matched sibling donor, with fludarabine and melphalan conditioning. The post-transplantation course was uneventful, except for mild skin acute graft-versus-host disease (grade 2). EBV-DNA became undetectable in peripheral blood 98 days post transplantation. She has since been in good health without disease recurrence. CAEBV is a potentially fatal disease caused by persistent EBV infection of T lymphocytes or natural killer cells, thus requiring prompt treatment and allogeneic transplantation. Pericardial effusion is rarely observed in CAEBV and can impede its diagnosis. Therefore, we should be aware that patients may present with marked pericardial effusion as an initial manifestation of CAEBV.

Entities:  

Mesh:

Year:  2016        PMID: 27263789     DOI: 10.11406/rinketsu.57.624

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  2 in total

Review 1.  A new therapy in Epstein-Barr virus-associated lymphoproliferative disease: a case report and a revision of the literature.

Authors:  Lingling Xu; Hongjun Ba; Hongrong Lin; Liangying Zhong; Suping Li; Wen Tang; Zhiyong Ke; Ziyin Ye
Journal:  Ital J Pediatr       Date:  2019-11-04       Impact factor: 2.638

2.  Massive pericardial effusion due to chronic active Epstein-Barr virus infection successfully treated with PD-1 blockade: A case report.

Authors:  Yubo Pi; Jingshi Wang; Zhao Wang
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.